Boldenone 250 is a testosterone derived anabolic androgenic steroid that is best known by the trade name Equipoise given to it by Squibb in the 1970’s. While
Equipoise is officially classified as a veterinarian grade anabolic steroid, the first batches of Boldenone were introduced on the human grade pharmaceutical market
by Ciba in the early 1950’s under the brand name Parenabol. Human grade Boldenone would see some success in human medicine through the 1960’s and 70’s but
would ultimately be discontinued by the end of the decade. Since that time, the steroid has only been available through veterinarian medicine and underground labs
with the Equipoise name dominating the market. Fort Dodge Animal Health now owns the Equipoise name.

For decades, it has been assumed that Boldenone was very similar to Deca (Nandrolone Decanoate). This assumption was in part based on comments the late Dan
Duchaine made about the steroid. However, the two compounds are not similar in any way; in fact, Duchaine would recant the statement, but the initial statement has
been enough to keep the rumor alive. If Boldenone shares anything in common with another anabolic steroidal hormone, it would be testosterone, but EQ as it’s
commonly known is unique in its own right. An important note regarding the differences in these two steroidal hormones; Nandrolone carries a strong progestin nature,
while Boldenone carries no progestin characteristics.

Boldenone Undecylenate is a structurally altered form of testosterone. It is a very slight change in an added double bond at the carbon one and two position.
This double bond greatly reduces the hormone’s androgenicity, as well as estrogenic nature. It is then attached to the very large or long Undecylenate ester, which is
responsible for controlling the release of the hormone once administered into the body. The Undecylenate ester allows for a peak release in Boldenone approximately
3-4 days after injection, with a slow continuous release of the hormone to follow for approximately 21 days.